Medvi's $1.8B Mirage: When AI Hype Masks Fraud

Medvi's meteoric rise to a $1.8 billion valuation was touted as an AI industry triumph, yet credible investigations reveal a company built on potential fraud and serious compliance violations. The New York Times' uncritical coverage failed to address concerns about data mishandling and vendor exploitation, exposing how AI industry hype can override due diligence. This case serves as a stark warning: in an environment of AI enthusiasm and regulatory gaps, fraudulent operations can scale to billions before proper scrutiny catches up.